Cambium Bio (ASX:CMB) Volatility: 108.94% (As of Jun. 26, 2026)


ASX:CMB Cambium Bio Ltd ASX:CMB
34 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Volatility?

Cambium Bio ASX:CMB -6.74% 34 Volatility is 108.94% as of Jun. 26, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-26), Cambium Bio's Volatility is 108.94%.

Cambium Bio  (ASX:CMB) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Cambium Bio Volatility Related Terms

ASX:CMB vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, Cambium Bio's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Volatility distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Volatility falls into.


ASX:CMB
34GF Score
Cambium Bio Ltd ASX:CMB
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio  (ASX:CMB) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 108.94% mean?
Cambium Bio (ASX:CMB) has a Volatility of 108.94% as of Jun. 26, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Cambium Bio and its competitors.
Is Cambium Bio's Volatility too high?
Cambium Bio's current Volatility is 108.94%. Overall, Cambium Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Volatility compare to VRTX and REGN?
Cambium Bio's Volatility of 108.94% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Cambium Bio and its competitors. Cambium Bio's current Volatility is 108.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Volatility of 108.94%. The current Volatility is 108.94%. Cambium Bio's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Volatility is 108.94% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
34GF Score

Get the complete analysis for ASX:CMB

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price